ConductScience.org, home
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
API referenceFor AI assistants

Trial · NCT00045942

Participant flow108

How many started, completed or left each group, period by period.

1 to 20 of 108

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
PKC412A2104 (Core)STARTEDPKC412 in FLT3 Mutated Participants (Core)20
PKC412A2104 (Core)STARTEDFLT3 Mutated PKC412 100 mg/Day (E1)0
PKC412A2104 (Core)STARTEDFLT3 Mutated PKC412 200 mg/Day (E1)0
PKC412A2104 (Core)STARTEDFLT3 Wild Type PKC412 100 mg/Day (E1)0
PKC412A2104 (Core)STARTEDFLT3 Wild Type PKC412 200 mg/Day (E1)0
PKC412A2104 (Core)STARTEDFLT3 Mutated PKC412 Dose Escalation (E2)0
PKC412A2104 (Core)STARTEDFLT3 Mutated PKC+Itraconazole (E2)0
PKC412A2104 (Core)STARTEDFLT3 Wild Type PKC412 Dose Escalation (E2)0
PKC412A2104 (Core)STARTEDFLT3 Wild Type PKC+Itraconazole (E2)0
PKC412A2104 (Core)Core Primary EfficacyPKC412 in FLT3 Mutated Participants (Core)20
PKC412A2104 (Core)Core Primary EfficacyFLT3 Mutated PKC412 100 mg/Day (E1)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Mutated PKC412 200 mg/Day (E1)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Wild Type PKC412 100 mg/Day (E1)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Wild Type PKC412 200 mg/Day (E1)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Mutated PKC412 Dose Escalation (E2)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Mutated PKC+Itraconazole (E2)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Wild Type PKC412 Dose Escalation (E2)0
PKC412A2104 (Core)Core Primary EfficacyFLT3 Wild Type PKC+Itraconazole (E2)0
PKC412A2104 (Core)COMPLETEDPKC412 in FLT3 Mutated Participants (Core)0
PKC412A2104 (Core)COMPLETEDFLT3 Mutated PKC412 100 mg/Day (E1)0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00045942/flow

API referenceFor AI assistants